AIM ImmunoTech Inc. Stock price

Equities

AIM

US00901B1052

Biotechnology & Medical Research

Delayed Nyse 10:55:00 2024-03-28 am EDT 5-day change 1st Jan Change
0.4688 USD +5.81% Intraday chart for AIM ImmunoTech Inc. +23.04% +6.57%
Sales 2023 * 157K Sales 2024 * 70K Capitalization 21.64M
Net income 2023 * -22M Net income 2024 * -27M EV / Sales 2023 * 138 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 309 x
P/E ratio 2023 *
-0.98 x
P/E ratio 2024 *
-0.98 x
Employees 23
Yield 2023 *
-
Yield 2024 *
-
Free-Float 91.31%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AIM ImmunoTech Inc.

1 day+0.91%
1 week+10.72%
Current month+10.47%
1 month+8.02%
3 months-10.18%
6 months-3.86%
Current year+0.70%
More quotes
1 week
0.38
Extreme 0.381
0.49
1 month
0.32
Extreme 0.3201
0.49
Current year
0.32
Extreme 0.3201
0.50
1 year
0.32
Extreme 0.3201
0.75
3 years
0.29
Extreme 0.291
2.51
5 years
0.29
Extreme 0.291
14.81
10 years
0.29
Extreme 0.291
221.23
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 08-11-16
Director of Finance/CFO 68 22-04-03
Chief Tech/Sci/R&D Officer - 22-05-31
Members of the board TitleAgeSince
Director/Board Member 66 23-03-27
Chairman 88 98-06-30
Chief Executive Officer 72 08-11-16
More insiders
Date Price Change Volume
24-03-28 0.4688 +5.81% 80 564
24-03-27 0.443 +0.91% 172,286
24-03-26 0.439 -0.23% 231,694
24-03-25 0.44 -0.83% 931,165
24-03-22 0.4437 +16.46% 197,288

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
AIM ImmunoTech Inc. is an immuno-pharmaceutical company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules and Alferon N Injection (Interferon Alfa-N3). Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.443 USD
Average target price
2.75 USD
Spread / Average Target
+520.77%
Consensus
  1. Stock
  2. Equities
  3. Stock AIM ImmunoTech Inc. - Nyse